SCHEMBL15219261

SCHEMBL15219261

Cc1nnc(CN2CCC(N)CC2)o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.39
MEN1 O00255 1/20 0.39
RAB9A P51151 2/20 0.39
MAPT P10636 4/20 0.35
GNAI3 P08754 1/20 0.34
GNAO1 P09471 1/20 0.34
GNAI1 P63096 1/20 0.34
ATM Q13315 2/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
KCNH2 Q12809 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
RPS6KA5 O75582 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33
SRPK1 Q96SB4 1/20 0.32
EGFR P00533 1/20 0.32
ERBB2 P04626 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11919177 0.83 KMT2A (0.39) KMT2AMEN1RAB9AMAPTGNAI3
SCHEMBL11915968 0.80 RAB9A (0.36) KMT2AMEN1RAB9AMAPTGNAI3
SCHEMBL22515493 0.80 RAB9A (0.39) KMT2AMEN1RAB9AMAPTGNAI3
SCHEMBL13631416 0.77 SMN1; SMN2 (0.43) KMT2AMEN1RAB9AMAPTATM
SCHEMBL18350597 0.73 LTA4H (0.35) KMT2AMEN1RAB9AGNAI3GNAO1
SCHEMBL11218649 0.73 SMN1; SMN2 (0.38) KMT2ARAB9AMAPTATMALDH1A1
SCHEMBL2276427 0.70 RIPK1 (0.42) KMT2AMEN1KCNH2HRH3
SCHEMBL18933195 0.67 CYP2D6 (0.39) HRH3
SCHEMBL17967794 0.67 ALDH1A1 (0.58) KMT2AMEN1MAPTALDH1A1POLB
SCHEMBL23152118 0.63 LTA4H (0.49) KMT2AMEN1ALDH1A1HRH3GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170218000-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. 2017-08-03 US disclosed
US-9273077-B2 Phosphorus derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2016-03-01 US disclosed
US-20150225436-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2015-08-13 US disclosed
US-9012462-B2 Phosphorous derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2015-04-21 US disclosed
US-8912330-B2 Azaindole derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-12-16 US disclosed
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. 2014-12-11 US disclosed
US-8846664-B2 Pyrazinopyrazines and derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-09-30 US disclosed
US-20140066406-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2014-03-06 US disclosed
US-20130225527-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-08-29 US disclosed
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-08-29 US disclosed
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066406-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 KMT2A 2366/4885MEN1 1313/4885RAB9A 2334/4885
US-20170218000-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS MAP3K6, PIK3CA, MAP3K20 KMT2A 1452/4885MEN1 826/4885RAB9A 1513/4885
US-20150225436-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS MAP3K6, PIK3CA, MAP3K20 KMT2A 1406/4885MEN1 1028/4885RAB9A 1490/4885
US-20140364423-A1 Pyrazinopyrazines and Derivatives as Kinase Inhibitors MAP3K5, MAP3K15, MAP4K2 KMT2A 1177/4885MEN1 2993/4885RAB9A 2309/4885
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ABL1, CDKN1A, MAP3K13 KMT2A 408/4885MEN1 1089/4885RAB9A 1616/4885
US-20130225527-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 KMT2A 2366/4885MEN1 1313/4885RAB9A 2334/4885
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 KMT2A 2366/4885MEN1 1313/4885RAB9A 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.